Listed

Mobia Medical, Inc.

MOBINasdaqCIK 1489993HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$13.5m, Q2 FY2026
Operating income−$17.9m, Q2 FY2026
Net income−$21.0m, Q2 FY2026
Mobia Medical, Inc., income statement, quarterly
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m5.7Revenue, period not labelled, three months to 2025-03-31$5.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure6.7Revenue, period not labelled, three months to 2025-06-30$6.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure12.1Revenue, Q1 FY2026, three months to 2026-03-31$12.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure13.5Revenue, Q2 FY2026, three months to 2026-06-30$13.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure
Cost of revenue$m1.0Cost of revenue, period not labelled, three months to 2025-03-31$1.0m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure1.2Cost of revenue, period not labelled, three months to 2025-06-30$1.2m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure2.1Cost of revenue, Q1 FY2026, three months to 2026-03-31$2.1m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure2.3Cost of revenue, Q2 FY2026, three months to 2026-06-30$2.3m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure
Gross profit$m4.6Gross profit, period not labelled, three months to 2025-03-31$4.6m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure5.5Gross profit, period not labelled, three months to 2025-06-30$5.5m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure9.9Gross profit, Q1 FY2026, three months to 2026-03-31$9.9m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure11.2Gross profit, Q2 FY2026, three months to 2026-06-30$11.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure
Research and development$m1.4Research and development, period not labelled, three months to 2025-03-31$1.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure1.4Research and development, period not labelled, three months to 2025-06-30$1.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure1.7Research and development, Q1 FY2026, three months to 2026-03-31$1.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure2.3Research and development, Q2 FY2026, three months to 2026-06-30$2.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure
Selling, general and administrative$m13.6Selling, general and administrative, period not labelled, three months to 2025-03-31$13.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure14.5Selling, general and administrative, period not labelled, three months to 2025-06-30$14.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure25.2Selling, general and administrative, Q1 FY2026, three months to 2026-03-31$25.2m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure26.9Selling, general and administrative, Q2 FY2026, three months to 2026-06-30$26.9m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure
Operating income$m(10.3)Operating income, period not labelled, three months to 2025-03-31−$10.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure(10.5)Operating income, period not labelled, three months to 2025-06-30−$10.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure(16.9)Operating income, Q1 FY2026, three months to 2026-03-31−$16.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure(17.9)Operating income, Q2 FY2026, three months to 2026-06-30−$17.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure
Interest expense$m0.2Interest expense, period not labelled, three months to 2025-03-31$239.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure0.2Interest expense, period not labelled, three months to 2025-06-30$241.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure0.4Interest expense, Q1 FY2026, three months to 2026-03-31$357.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure0.3Interest expense, Q2 FY2026, three months to 2026-06-30$254.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure
Income tax$m0.0Income tax, period not labelled, three months to 2025-03-31$1.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure0.0Income tax, period not labelled, three months to 2025-06-30$2.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$2.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure
Net income$m(10.7)Net income, period not labelled, three months to 2025-03-31−$10.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure(10.5)Net income, period not labelled, three months to 2025-06-30−$10.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure(17.7)Net income, Q1 FY2026, three months to 2026-03-31−$17.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure(21.0)Net income, Q2 FY2026, three months to 2026-06-30−$21.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure
Diluted EPS$ per share(12.97)Diluted EPS, period not labelled, three months to 2025-03-31−$12.97 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure(12.44)Diluted EPS, period not labelled, three months to 2025-06-30−$12.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure(19.30)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$19.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure(1.10)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure
Basic EPS$ per share(12.97)Basic EPS, period not labelled, three months to 2025-03-31−$12.97 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure(12.44)Basic EPS, period not labelled, three months to 2025-06-30−$12.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure(19.30)Basic EPS, Q1 FY2026, three months to 2026-03-31−$19.30 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure(1.10)Basic EPS, Q2 FY2026, three months to 2026-06-30−$1.10 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure

Balance sheet

Cash and equivalents$177.1m, Q2 FY2026
Shareholders' equity$172.6m, Q2 FY2026
Mobia Medical, Inc., balance sheet, quarterly
Line itemUnitperiod not labelled2024-12-31period not labelled2025-03-31period not labelled2025-06-30period not labelled2025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$mnot reportednot reportednot reported33.6Cash and equivalents, period not labelled, at 2025-12-31$33.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure55.7Cash and equivalents, Q1 FY2026, at 2026-03-31$55.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure177Cash and equivalents, Q2 FY2026, at 2026-06-30$177.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure
Current assets$mnot reportednot reportednot reported46.4Current assets, period not labelled, at 2025-12-31$46.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure71.7Current assets, Q1 FY2026, at 2026-03-31$71.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure192Current assets, Q2 FY2026, at 2026-06-30$192.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure
Total assets$mnot reportednot reportednot reported48.1Total assets, period not labelled, at 2025-12-31$48.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure73.6Total assets, Q1 FY2026, at 2026-03-31$73.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure195Total assets, Q2 FY2026, at 2026-06-30$195.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure
Current liabilities$mnot reportednot reportednot reported10.2Current liabilities, period not labelled, at 2025-12-31$10.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure11.8Current liabilities, Q1 FY2026, at 2026-03-31$11.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure14.5Current liabilities, Q2 FY2026, at 2026-06-30$14.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure
Total liabilities$mnot reportednot reportednot reported19.1Total liabilities, period not labelled, at 2025-12-31$19.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure61.6Total liabilities, Q1 FY2026, at 2026-03-31$61.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure22.7Total liabilities, Q2 FY2026, at 2026-06-30$22.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure
Shareholders' equity$m(106)Shareholders' equity, period not labelled, at 2024-12-31−$106.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure(116)Shareholders' equity, period not labelled, at 2025-03-31−$116.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure(126)Shareholders' equity, period not labelled, at 2025-06-30−$126.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure(151)Shareholders' equity, period not labelled, at 2025-12-31−$150.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure(168)Shareholders' equity, Q1 FY2026, at 2026-03-31−$167.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure173Shareholders' equity, Q2 FY2026, at 2026-06-30$172.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure

Cash flow

Operating cash flow−$15.7m, Q2 FY2026
Capital expenditure$1.5m, Q2 FY2026
Mobia Medical, Inc., cash flow, quarterly
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(9.7)Operating cash flow, period not labelled, three months to 2025-03-31−$9.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure(11.0)Operating cash flow, period not labelled, three months to 2025-06-30−$11.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-344893. Derived: 6-month figure less the 3-month figure.Report this figure(17.7)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$17.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure(15.7)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$15.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-344893. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, period not labelled, three months to 2025-03-31$23.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure0.0Capital expenditure, period not labelled, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001193125-26-344893. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$42.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure1.5Capital expenditure, Q2 FY2026, three months to 2026-06-30$1.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001193125-26-344893. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)19.09m, Q2 FY2026
Mobia Medical, Inc., shares, quarterly
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares0.8Diluted shares (weighted), period not labelled, three months to 2025-03-31821,160 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure0.8Diluted shares (weighted), period not labelled, three months to 2025-06-30843,168 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure0.9Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31918,935 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-06-04, accession 0001193125-26-257552.Report this figure19.1Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3019,089,211 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure

Shares outstanding: 33.29mShares outstanding, period not labelled, at 2026-08-0633,291,096 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344893.Report this figure at Aug 6, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. Listed shows no prices and gives no investment advice.